KRKA - Decision of the Court of Appeal in esomeprazole case in the Great Britain

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 22 / 2015

Date of issue: 2015-05-22

Short name of the issuer

KRKA

Subject

Decision of the Court of Appeal in esomeprazole case in the Great Britain

Official market - legal basis

Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne

Unofficial market - legal basis

Contents of the report:

Krka, d.d., Novo mesto (hereafter referred to as Krka) is informing the public that Krka has received the decision of the Court of Appeal in London refused the appeal filed by AstraZeneca AB, Sweden and AstraZeneca UK Limited (hereinafter collectively referred to as AstraZeneca) which requested that the Appeals Court set aside the decision of the High Court of Justice, Patents Court in London which awarded to Krka damages and legal costs in the total amount of slightly less than EUR 21 million for losses Krka has suffered because it was injuncted to sell esomeprazole between mid-2010 to mid-2011 because alleged infringement of AstraZeneca's patent EP 1 020 461 . AstraZeneca can request a leave to appeal at the Supreme Court. Krka has formed provisions for the assigned amount that will be released when the decision is final and all legal means are exhausted Krka published the announcement considering esomeprazole litigation in the Great Britain on 7 April 2014.

Annexes

File Description

KRKA, TOVARNA ZDRAVIL D.D.

(fullname of the issuer)

KRKA Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

8501 Nove Mesto

(post code) (city)

Smarjeska 6

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

SI82646716

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2015-05-22 Jo¾e Colariè President of the Management Board